These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35149986)

  • 1. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Ujjani C; Shadman M; Lynch RC; Tu B; Stevenson PA; Grainger C; Zhu H; Hill JA; Huang ML; Nielsen L; Poh C; Sorensen T; Gopal AK; Warren EH; Till BG; Lee S; Gausman D; Smith SD; Gooley T; Greninger A
    Br J Haematol; 2022 May; 197(3):306-309. PubMed ID: 35149986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
    J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
    J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
    Sorcini D; De Falco F; Gargaro M; Bozza S; Guarente V; Cardinali V; Stella A; Adamo FM; Silva Barcelos EC; Rompietti C; Dorillo E; Geraci C; Esposito A; Arcaleni R; Capoccia S; Mameli MG; Graziani A; Moretti L; Cipiciani A; Riccardi C; Mencacci A; Fallarino F; Rosati E; Sportoletti P
    Br J Haematol; 2023 Apr; 201(1):45-57. PubMed ID: 36484163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 vaccination in CLL: how often is enough?
    Mellinghoff SC; Cornely OA
    Blood; 2022 Dec; 140(25):2655-2657. PubMed ID: 36548017
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
    Shen Y; Freeman JA; Holland J; Naidu K; Solterbeck A; Van Bilsen N; Downe P; Kerridge I; Wallman L; Akerman A; Aggarwal A; Milogiannakis V; Martins Costa Gomes G; Doyle CM; Sandgren KJ; Turville S; Cunningham AL; Mulligan SP
    Blood; 2022 Dec; 140(25):2709-2721. PubMed ID: 36206503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients.
    Fattizzo B; Bortolotti M; Rampi N; Cavallaro F; Giannotta JA; Bucelli C; Cassin R; Da Vià MC; Galassi G; Noto A; Pettine L; Rossi FG; Sciumè M; Ceriotti F; Consonni D; Barcellini W; Baldini L
    Front Immunol; 2022; 13():852158. PubMed ID: 35634287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience.
    Baratè C; Caruso T; Mavilia F; Sammuri P; Pratesi F; Motta G; Guerri V; Galimberti S; Migliorini P
    Clin Exp Med; 2023 Aug; 23(4):1197-1203. PubMed ID: 36074205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
    Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
    Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
    Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
    Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
    Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
    Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
    Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP
    Br J Haematol; 2022 Apr; 197(1):41-51. PubMed ID: 34962656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.
    Healy K; Pin E; Chen P; Söderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Loré K; Hellström C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren HG; Hober S; Nilsson P; Aleman S; Sällberg Chen M
    Med; 2022 Feb; 3(2):137-153.e3. PubMed ID: 35075450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
    Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
    Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.